Interesting presentation shared by Dr Amy C Moore

We are a charity now!

Currently watching the Lung Cancer Europe webinar on Clinical trials. Very disappointing & disturbing trend across Europe with 60,000 fewer places for patients. Clinical trials offer hope to #lungcancer patients when approved treatments have stopped working. We need to do better.

🔥 Journal of Clinical Oncology ASCO 🆙 ✅TRUST: Taletrectinib in ROS1+ NSCLC 🎯TKI-naïve/pretreated: ORR 88.8/55.8%, Intracranial-ORR 76.5/65.6%, mPFS 45.6/9.7mo 👥 Maurice Perol Nathan A. Pennell MD, PhD, FASCO Misako Nagasaka Enriqueta Felip Dr. Caicun Zhou #LCSM OncoAlert The ROS1ders, Inc. ROS1DERS UK ascopubs.org/doi/full/10.12…

This review summarizes a practical approach to the management of metastatic ROS1 fusion-positive NSCLC, integrating the most up-to-date, evolving evidence behind ROS1 inhibitors and beyond. #ROS1 #LCSM JessicaJLinMD doi.org/10.1093/oncolo…

🚨Sac-TMT vs. docetaxel in metastatic EGFRmut Lung cancer. RR: 45% vs 15% OS: NR with HR 0.49 PFS: 6.9 vs 2.8 months HR 0.30 Great data. We are fortunate to have MK2870 trial for 3rd line oncogenic driven lung Ca Barts Cancer Centre - good option for patients in UK!

We’ve just launched our new website! We are fighting for a rare lung cancer that’s been ignored for too long in the UK. We’re a brand new charity (no: 1212647) and need your help to kickstart our mission 🙏 Please consider donating: ros1ders-cancer.uk/donate/

Last week ROS1ders UK was UK Parliament to talk about - Inadequate access to life-saving drugs for UK ROS1+ cancer patients - Awareness of this overlooked cancer Grateful to MPs like Sarah Edwards for Tamworth, @DrNeilShastriHurstMP, Martin Vickers & Paula Barker for extending support

We are exhibiting at Lung Cancer Nursing UK Conference

Who said lung cancer exhibits can’t be fun?? Thank you to every nurse who brought their energy, questions, and kindness Lung Cancer Nursing UK Roy Castle Lung Cancer Foundation Ruth Strauss Foundation EGFR Positive Lung Cancer UK UKALK+ Sanjay Popat Tom Newsom-Davis European Lung Foundation American Lung Association UKLCC

Today, we shared positive topline results for zidesamtinib in TKI pre-treated patients with advanced ROS1+ NSCLC from our global Phase 1/2 ARROS-1 clinical trial. Learn more here: investors.nuvalent.com/2025-06-24-Nuv…

ROS1+ Patients (UK) – Next-Line TKIs As discussed, I kindly request Dr. Newsom Davis (Tom Newsom-Davis) to share the following information with oncologists: UK ROS1-positive patients currently have two next-line treatment options: Option 1) NVL-520: An Expanded Access Program

Are you a parent living with lung cancer? We are inviting parents of young people aged 11–24, along with their children, to take part in an online survey about wellbeing and support needs for families affected by lung cancer. Your insights will help improve and shape the support

The UK is now the first country to allow bedside manufacture of personalised cancer therapies. It’s a major regulatory shift with global implications that could mean faster, more flexible delivery of treatments built from a person’s own cells. For #lungcancer, that’s the